Shanghai Junshi Bioscience Co., Ltd. clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 100 studies whose lead sponsor is Shanghai Junshi Bioscience Co., Ltd.. 20 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the Shanghai Junshi Bioscience Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions Shanghai Junshi Bioscience Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 100. Browse all 100 →
- A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)Not yet recruitingNCT07876557Phase 2
- A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07808827Phase 3
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerNot yet recruitingNCT07823348Phase 3
- Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)RecruitingNCT06095583Phase 3
- A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid TumourRecruitingNCT06888830Phase 1/2
- JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II StudyRecruitingNCT07518160Phase 2
- A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced MalignanciesRecruitingNCT06839105Phase 1
- Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid TumorsRecruitingNCT07480733Phase 2
- Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI TherapyRecruitingNCT06868836Phase 2
- A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung CancerRecruitingNCT07309276Phase 2
- JS212 Combination Therapies in Metastatic Colorectal CancerRecruitingNCT07503756Phase 2
- A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07484724Phase 2
- JS207 Combination Therapy in Triple-negative Breast CancerRecruitingNCT07045311Phase 2
- JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.RecruitingNCT07284134Phase 3
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Phase 2
- A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal CancerRecruitingNCT06885385Phase 2
- Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III StudyRecruitingNCT05342194Phase 3
- A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)RecruitingNCT06170489Phase 3
- Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed DyslipidemiaRecruitingNCT05621070Phase 3
- A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401RecruitingNCT06041165Phase 1
- Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and ImmunotherapyTerminatedNCT06924606Phase 2
- JS203 Combination Regimens in B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT07081022Phase 2
- Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy VolunteersCompletedNCT04220073Phase 1
- A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid TumorsCompletedNCT06139211Phase 1/2
- Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical ResectionActive, not recruitingNCT03859128Phase 2/3
- A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05502393Phase 1
- Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKICompletedNCT03924050Phase 3
- A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell CancerCompletedNCT04856631Phase 1/2
- JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLCActive, not recruitingNCT06969027Phase 2
- Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.TerminatedNCT04797702Phase 1/2
- A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific MarkersTerminatedNCT04603040Phase 2
- The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by SurgeryTerminatedNCT03178123Phase 2
- JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLCActive, not recruitingNCT06944470Phase 2
- Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLCCompletedNCT04158440Phase 3
- Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpATerminatedNCT05242588Phase 2
- Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active ASCompletedNCT05212051Phase 2
- A Clinical Study of JS005 in Patients With Ankylosing SpondylitisCompletedNCT06250062Phase 2
- A Phase I Study Of JS015 in Patients With Advanced Solid TumorsCompletedNCT05770310Phase 1
- A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy SubjectsCompletedNCT06158737Phase 1
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Phase 3
- A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial CarcinomaWithdrawnNCT04568304Phase 3
- A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)CompletedNCT04605796Phase 2
- The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced TumorCompletedNCT05061628Phase 1
- A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid TumorsCompletedNCT04773951Phase 1
- A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal CarcinomaCompletedNCT05751486Phase 1
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Phase 3
- Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid TumorsActive, not recruitingNCT06571422Phase 1
- Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCCActive, not recruitingNCT04523493Phase 3
- The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant TumorActive, not recruitingNCT06022250Phase 1
- Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentCompletedNCT04085276Phase 3